PolyPid (PYPD) News Today → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free PYPD Stock Alerts $4.44 -0.30 (-6.33%) (As of 05/16/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 2:39 AM | americanbankingnews.comHC Wainwright Reaffirms Buy Rating for PolyPid (NASDAQ:PYPD)May 12, 2024 | investing.comEarnings call: PolyPid reports progress in D-PLEX100 trial, eyes expansionMay 10, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call TranscriptMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on D-PLEX Progress and Solid Financial FootingMay 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PolyPid (PYPD) and Cartesian Therapeutics (RNAC)May 8, 2024 | investorplace.comPYPD Stock Earnings: PolyPid Beats EPS for Q1 2024May 8, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | americanbankingnews.comPolyPid (PYPD) Scheduled to Post Quarterly Earnings on WednesdayMay 1, 2024 | globenewswire.comPolyPid to Participate in Citizens JMP Life Sciences ConferenceApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for PolyPid on Strong Trial Progress and Expanding Pipeline PotentialApril 30, 2024 | globenewswire.comPolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site InfectionsApril 24, 2024 | msn.comPYPD: Polypid is Enhancing Surgical OutcomesApril 24, 2024 | globenewswire.comPolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024April 18, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2024 | globenewswire.comPolyPid to Participate in Barclays 26th Annual Global Healthcare ConferenceFebruary 19, 2024 | finance.yahoo.comPolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?February 15, 2024 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call TranscriptFebruary 14, 2024 | markets.businessinsider.comBuy Rating for PolyPid Amid Positive D-PLEX100 Trial Prospects and Strategic Market PositioningFebruary 14, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 14, 2024 | globenewswire.comPolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 12, 2024 | finanznachrichten.dePolyPid Ltd.: PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialFebruary 12, 2024 | finance.yahoo.comPolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 TrialJanuary 31, 2024 | finance.yahoo.comPolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024January 5, 2024 | msn.comWhy Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day SessionJanuary 5, 2024 | msn.comCyclacel Pharmaceuticals, Angiodynamic among healthcare moversJanuary 4, 2024 | uk.finance.yahoo.comPolyPid Ltd. (PYPD)January 4, 2024 | msn.comPolyPid looks to raise $16.2M through private placementJanuary 4, 2024 | finance.yahoo.comPolyPid Announces Private Placement for $16 Million in Gross ProceedsJanuary 2, 2024 | marketbeat.comTrading was temporarily halted for "PYPD" at 11:01 AM with a stated reason of "LULD pause."November 12, 2023 | finance.yahoo.comPolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call TranscriptNovember 12, 2023 | investing.comEarnings call: PolyPid's Q3 2023 financial results show decreased expenses and progress in SHIELD II trialNovember 8, 2023 | finance.yahoo.comPolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial ResultsNovember 7, 2023 | benzinga.comPolyPid's Earnings: A PreviewNovember 7, 2023 | finance.yahoo.comPolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of DirectorsNovember 1, 2023 | finance.yahoo.comPolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023October 24, 2023 | msn.comBarclays Maintains Polypid (PYPD) Equal-Weight RecommendationOctober 19, 2023 | finance.yahoo.comPolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price RuleOctober 13, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Polypid (PYPD) with Buy RecommendationOctober 12, 2023 | markets.businessinsider.comPromising Clinical Trials and Innovative PLEX Technology Drive Analyst’s Buy Rating for PolyPid Ltd.October 9, 2023 | markets.businessinsider.comResilient PolyPid Maintains Buy Rating Despite Challenges: An Analysis of Ongoing Trials and Financial AdjustmentsOctober 9, 2023 | finance.yahoo.comPolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023October 5, 2023 | msn.comPolypid (PYPD) Price Target Increased by 2900.00% to 68.85October 4, 2023 | finance.yahoo.comPolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology PlatformSeptember 22, 2023 | finance.yahoo.comPolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare ConferenceSeptember 22, 2023 | marketbeat.comTrading was temporarily halted for "PYPD" at 09:09 AM with a stated reason of "LULD pause."September 21, 2023 | marketbeat.comTrading was temporarily halted for "PYPD" at 11:09 AM with a stated reason of "LULD pause."September 21, 2023 | finance.yahoo.comPolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of HealthSeptember 20, 2023 | finance.yahoo.comPolyPid Announces Reverse Share SplitSeptember 19, 2023 | marketwatch.comPolyPid Completes Manufacturing-Process Validation for D-PLEX Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. PYPD Media Mentions By Week PYPD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PYPD News Sentiment▼0.900.55▲Average Medical News Sentiment PYPD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PYPD Articles This Week▼61▲PYPD Articles Average Week Get PolyPid News Delivered to You Automatically Sign up to receive the latest news and ratings for PYPD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Nephros News PAVmed News Lyra Therapeutics News Meihua International Medical Technologies News Inspira Technologies Oxy B.H.N. News T2 Biosystems News Spectral AI News NeuroOne Medical Technologies News GlucoTrack News Femasys News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PYPD) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersGold Set to EXPLODE!Gold Safe ExchangeWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsWhy Is Gold On a MASSIVE rally? Huge AlertsThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PolyPid Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
